Pricing Log in Create free account

Apollomics Inc. (APLM) vs Xilio Therapeutics, Inc. (XLO)

Apollomics Inc. and Xilio Therapeutics, Inc. are both Biotechnology companies. Xilio Therapeutics, Inc. is the larger, with a market value of $59.2M against $53.2M — 1.1× the size. Apollomics Inc. has the higher net margin (0.00% vs −34.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 9 metrics below, Apollomics Inc. leads on 8 and Xilio Therapeutics, Inc. on 1.

Valuation

Metric APLM XLO Biotechnology median
P/E n/m n/m 10.85
P/S — 2.72 9.49
P/B n/m 2.41 2.18
Price to free cash flow n/m n/m 25.85
EV/EBITDA n/m n/m 0.70
EV/Sales n/m 0.62 8.99
Earnings yield (0.33%) (16.62%) (31.76%)
Free cash flow yield 0.00% (35.20%) (21.84%)

Profitability

Metric APLM XLO Biotechnology median
Gross margin — 100.00% 68.51%
Operating margin — (48.94%) 0.00%
Net margin 0.00% (34.06%) 0.00%
Free cash flow margin 0.00% (95.59%) 0.00%
Return on equity 0.00% (55.03%) (50.82%)
Return on assets 0.00% (15.16%) (46.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric APLM XLO Biotechnology median
Revenue growth (TTM) — 327.25% 6.96%
EPS growth (last fiscal year) 85.66% 72.55% 29.88%
Revenue growth, 5-year CAGR 32.77% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric APLM XLO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.96 4.25 4.84
Net debt to EBITDA 0.37 3.40 1.01

Dividend

Metric APLM XLO Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric APLM XLO Biotechnology median
Market cap 53.19m 59.22m 163.56m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack